Seçici Serotonin Geri Alım İnhibitörlerinin Terapötik İlaç Düzeyi İzleminde LC-MS/MS Yöntemleri

Altar CA, Neurotrophins and depression. Trends in pharmacological sciences. 1999; 20: 59-62. https://doi.org/10.1016/S0165-6147(99)01309-7

Depression W, Other common mental disorders: global health estimates. Geneva: World Health Organization. 2017.

Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB, Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. Jama. 2011; 306: 1241-1249. https://doi.org/10.1001/jama.2011.1282

Deussing JM, Animal models of depression. Drug discovery today: disease models. 2006; 3: 375-383. https://doi.org/10.1016/j.ddmod.2006.11.003

Fostick L, Silberman A, Beckman M, Spivak B, Amital D, The economic impact of depression: resistance or severity? European Neuropsychopharmacology. 2010; 20: 671-675. https://doi.org/10.1016/j.euroneuro.2010.06.001

Hasler G, Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World psychiatry. 2010; 9: 155. https://doi.org/10.1002/j.2051-5545.2010.tb00298.x

Dell'Osso L, Carmassi C, Mucci F, Marazziti D, Depression, serotonin and tryptophan. Current pharmaceutical design. 2016; 22: 949-954. https://doi.org/10.2174/1381612822666151214104826

Sghendo L, Mifsud J, Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model. Journal of Pharmacy and Pharmacology. 2012; 64: 317-325. https://doi.org/10.1111/j.2042-7158.2011.01384.x

Cowen PJ, Browning M, What has serotonin to do with depression? World psychiatry. 2015; 14: 158. https://doi.org/10.1002/wps.20229

Van der Does AW, The effects of tryptophan depletion on mood and psychiatric symptoms. Journal of affective disorders. 2001; 64: 107-119. https://doi.org/10.1016/S0165-0327(00)00209-3

Turner EH, Loftis JM, Blackwell AD, Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology & therapeutics. 2006; 109: 325-338. https://doi.org/10.1016/j.pharmthera.2005.06.004

Bell C, Abrams J, Nutt D, Tryptophan depletion and its implications for psychiatry. The British Journal of Psychiatry. 2001; 178: 399-405. https://doi.org/10.1192/bjp.178.5.399

Young SN, Leyton M, The role of serotonin in human mood and social interaction: insight from altered tryptophan levels. Pharmacology Biochemistry and Behavior. 2002; 71: 857-865. https://doi.org/10.1016/S0091-3057(01)00670-0

Vaswani M, Linda FK, Ramesh S, Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Progress in neuro-psychopharmacology and biological psychiatry. 2003; 27: 85-102. https://doi.org/10.1016/S0278-5846(02)00338-X

Masand PS, Gupta S, Selective serotonin-reuptake inhibitors: an update. Harvard review of psychiatry. 1999; 7: 69-84. https://doi.org/10.3109/hrp.7.2.69

Gautam S, Jain A, Gautam M, Vahia VN, Grover S, Clinical practice guidelines for the management of depression. Indian journal of psychiatry. 2017; 59: S34. https://doi.org/10.4103/0019-5545.196973

Lochmann, D., Richardson, T. (2018). Selective Serotonin Reuptake Inhibitors. In: Macaluso, M., Preskorn, S. (eds) Antidepressants. Handbook of Experimental Pharmacology, vol 250. Springer, Cham. https://doi.org/10.1007/164_2018_172

van Harten J, Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clinical pharmacokinetics. 1993; 24: 203-220. https://doi.org/10.2165/00003088-199324030-00003

Preskorn SH, Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clinical pharmacokinetics. 1997; 32: 1-21. https://doi.org/10.2165/00003088-199700321-00003

Carrasco J, Sandner C, Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. International journal of clinical practice. 2005; 59: 1428-1434. https://doi.org/10.1111/j.1368-5031.2005.00681.x

Wong DT, Perry KW, Bymaster FP, The discovery of fluoxetine hydrochloride (Prozac). Nature reviews Drug discovery. 2005; 4: 764-774. https://doi.org/10.1038/nrd1821

Hiemke C, Härtter S, Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology & therapeutics. 2000; 85: 11-28. https://doi.org/10.1016/S0163-7258(99)00048-0

Altamura AC, Moro AR, Percudani M, Clinical pharmacokinetics of fluoxetine. Clinical pharmacokinetics. 1994; 26: 201-214. https://doi.org/10.2165/00003088-199426030-00004

Mandrioli R, Forti GC, Raggi M, Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Current drug metabolism. 2006; 7: 127-133. https://doi.org/10.2174/138920006775541561

Bergstrom R, Lemberger L, Farid N, Wolen R, Clinical pharmacology and pharmacokinetics of fluoxetine: a review. The British Journal of Psychiatry. 1988; 153: 47-50. https://doi.org/10.1192/S0007125000297286

Cooke M, Waring W, Citalopram and cardiac toxicity. European journal of clinical pharmacology. 2013; 69: 755-760. https://doi.org/10.1007/s00228-012-1408-1

Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C, Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology. 2004; 174: 163-176. https://doi.org/10.1007/s00213-004-1865-z

Sangkuhl K, Klein TE, Altman RB, PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenetics and genomics. 2011; 21: 769. https://doi.org/10.1097/FPC.0b013e328346063f

Kwon JW, Armbrust KL, Degradation of citalopram by simulated sunlight. Environmental Toxicology and Chemistry: An International Journal. 2005; 24: 1618-1623. https://doi.org/10.1897/04-522R.1

Carandang C, Jabbal R, MacBride A, Elbe D, A review of escitalopram and citalopram in child and adolescent depression. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2011, 20, 315

Yang LP, Scott LJ, Escitalopram: in the treatment of major depressive disorder in adolescent patients. Pediatric Drugs. 2010; 12: 155-162. https://doi.org/10.2165/11204340-000000000-00000

Søgaard B, Mengel H, Rao N, Larsen F, The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. The Journal of Clinical Pharmacology. 2005; 45: 1400-1406. https://doi.org/10.1177/0091270005280860

Rao N, The clinical pharmacokinetics of escitalopram. Clinical pharmacokinetics. 2007; 46: 281-290. https://doi.org/10.2165/00003088-200746040-00002

Altamura AC, Caldiroli A, Buoli M, Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders. Expert Opinion on Drug Metabolism & Toxicology. 2015; 11: 649-660. https://doi.org/10.1517/17425255.2015.1021331

Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV, Fluvoxamine: a review of its mechanism of action and its role in COVID-19. Frontiers in pharmacology. 2021; 12: 763. https://doi.org/10.3389/fphar.2021.652688

Figgitt DP, McClellan KJ, Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs. 2000: 60; 925-954. https://doi.org/10.2165/00003495-200060040-00006

Connor DF, Brent DA, Riddle MA, Paroxetine and the FDA. Journal of the American Academy of Child and Adolescent Psychiatry. 2004; 43: 127-129. https://doi.org/10.1097/00004583-200402000-00001

Marks DM, Park M-H, Ham B-J, Han C, Patkar AA, Masand PS, Pae C-U, Paroxetine: safety and tolerability issues. Expert opinion on drug safety. 2008; 7: 783-794. https://doi.org/10.1517/14740330802423168

Bourin M, Chue P, Guillon Y, Paroxetine: a review. CNS drug reviews. 2001; 7: 25-47. https://doi.org/10.1111/j.1527-3458.2001.tb00189.x

Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL, Paroxetine: an update of its use in psychiatric disorders in adults. Drugs. 2002; 62: 655-703. https://doi.org/10.2165/00003495-200262040-00010

McRae AL, Brady KT, Review of sertraline and its clinical applications in psychiatric disorders. Expert Opinion on Pharmacotherapy. 2001; 2: 883-892. https://doi.org/10.1517/14656566.2.5.883

De Vane CL, Liston HL, Markowitz JS, Clinical pharmacokinetics of sertraline. Clinical pharmacokinetics. 2002; 41: 1247-1266. https://doi.org/10.2165/00003088-200241150-00002

Plenge P, Yang D, Salomon K, Laursen L, Kalenderoglou IE, Newman AH, Gouaux E, Coleman JA, Loland CJ, The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter. Nature Communications. 2021; 12: 5063. https://doi.org/10.1038/s41467-021-25363-3

Sahli ZT, Banerjee P, Tarazi FI, The preclinical and clinical effects of vilazodone for the treatment of major depressive disorder. Expert opinion on drug discovery. 2016; 11: 515-523. https://doi.org/10.1517/17460441.2016.1160051

Wang S-M, Han C, Lee S-J, Patkar AA, Masand PS, Pae C-U, A review of current evidence for vilazodone in major depressive disorder. International journal of psychiatry in clinical practice. 2013; 17: 160-169. https://doi.org/10.3109/13651501.2013.794245

Frampton JE, Vilazodone: in major depressive disorder. CNS drugs. 2011; 25: 615-627. https://doi.org/10.2165/11207550-000000000-00000

McCormack PL, Vilazodone: a review in major depressive disorder in adults. Drugs. 2015; 75: 1915-1923. https://doi.org/10.1007/s40265-015-0490-y

Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME, An overview of vortioxetine. The Journal of clinical psychiatry. 2014; 75: 13677. https://doi.org/10.4088/JCP.14027ah1

Connolly KR, Thase ME, Vortioxetine: a new treatment for major depressive disorder. Expert Opinion on Pharmacotherapy. 2016; 17: 421-431. https://doi.org/10.1517/14656566.2016.1133588

Frampton JE, Vortioxetine: a review in cognitive dysfunction in depression. Drugs. 2016; 76: 1675-1682 https://doi.org/10.1007/s40265-016-0655-3

Gibb A, Deeks ED, Vortioxetine: first global approval. Drugs. 2014; 74: 135-145 https://doi.org/10.1007/s40265-013-0161-9

Chen G, Højer A-M, Areberg J, Nomikos G, Vortioxetine: clinical pharmacokinetics and drug interactions. Clinical pharmacokinetics. 2018; 57: 673-686. https://doi.org/10.1007/s40262-017-0612-7

D’agostino A, English CD, Rey JA, Vortioxetine (brintellix): a new serotonergic antidepressant. Pharmacy and Therapeutics. 2015, 40, 36.

Bowers LD, Analytical goals in therapeutic drug monitoring. Clinical chemistry. 1998; 44: 375-380. https://doi.org/10.1093/clinchem/44.2.375

Kang J-S, Lee M-H, Overview of therapeutic drug monitoring. The Korean journal of internal medicine. 2009; 24: 1. https://doi.org/10.3904/kjim.2009.24.1.1

Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl M-L, Therapeutic drug monitoring for tomorrow. European journal of clinical pharmacology. 2013; 69: 25-32. https://doi.org/10.1007/s00228-013-1504-x

Hiemke C, Bergemann N, Clement H, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018; 51: 9-62. https://doi.org/10.1007/10.1055/s-0043-116492

Ghiculescu R, Therapeutic drug monitoring: which drugs, why, when and how to do it. Australian Prescriber. 2008; 31: https://doi.org/10.18773/austprescr.2008.025

Preskorn SH, Fast GA, Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. The Journal of clinical psychiatry. 1991; 52: 23-33.

Mabilat C, Gros MF, Nicolau D, Mouton JW, Textoris J, Roberts JA, Cotta MO, van Belkum A, Caniaux I, Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. European Journal of Clinical Microbiology & Infectious Diseases. 2020; 39: 791-797. https://doi.org/10.1007/s10096-019-03769-8

Burke MJ, Preskorn SH, Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clinical pharmacokinetics. 1999; 37: 147-165. https://doi.org/10.2165/00003088-199937020-00004

Gross AS, Best practice in therapeutic drug monitoring. British Journal of Clinical Pharmacology. 2001; 52: 5-9. https://doi.org/10.1111/j.1365-2125.2001.00770.x

Tuzimski T, Petruczynik A, Review of chromatographic methods coupled with modern detection techniques applied in the therapeutic drugs monitoring (TDM). Molecules. 2020; 25: 4026. https://doi.org/10.3390/molecules25174026

Ates HC, Roberts JA, Lipman J, Cass AE, Urban GA, Dincer C, On-site therapeutic drug monitoring. Trends in biotechnology. 2020; 38: 1262-1277. https://doi.org/10.1016/j.tibtech.2020.03.001

Huber CG, Oberacher H, Analysis of nucleic acids by on‐line liquid chromatography–Mass spectrometry. Mass Spectrometry Reviews. 2001; 20: 310-343. https://doi.org/10.1002/mas.10011

Douxfils J, Pochet L, Lessire S, Vancraeynest C, Dogné J-M, Mullier F, Mass spectrometry in the therapeutic drug monitoring of direct oral anticoagulants. Useful or useless? TrAC Trends in Analytical Chemistry. 2016; 84: 41-50. https://doi.org/10.1016/j.trac.2016.01.029

Cao X, Chen X, Zhang Y, Zhong D, Determination of citalopram in human plasma with LC-MS/MS method and its bioequivalent evaluation. Yao xue xue bao= Acta Pharmaceutica Sinica. 2007; 42: 450-454. http://doi.org/10.1109/5.771073

Singh SS, Shah H, Gupta S, Jain M, Sharma K, Thakkar P, Shah R, Liquid chromatography–electrospray ionisation mass spectrometry method for the determination of escitalopram in human plasma and its application in bioequivalence study. Journal of Chromatography B. 2004; 811, 209-215. https://doi.org/10.1016/j.jchromb.2004.09.001

Canbolat F, Tasdemir Erinç DM, Evrensel A, Aydın A, Tarhan KN, Quantitation of escitalopram and its metabolites by liquid chromatography‐tandem mass spectrometry in psychiatric patients: New metabolic ratio establishment. Basic & Clinical Pharmacology & Toxicology. 2019; 124: 285-297. https://doi.org/10.1111/bcpt.13133

Shah HJ, Kundlik ML, Kakad A, Patel NK, Pandya A, Khatri V, Prajapati S, Subbaiah G, Patel CN, Quantification of paroxetine in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Journal of AOAC International. 2010; 93: 141-149. https://doi.org/10.1093/jaoac/93.1.141

Jhee OH, Seo HK, Lee MH, Jeon YC, Shaw LM, Lee SH, Hur Y, Kim K-H, Lee H-S, Lee SE, Determination of Paroxetine in Plasma by Liquid Chromatography Coupled to Tandem Mass Spectrometry for Pharmacokinetic and Bio equivalence Studies. Arzneimittelforschung. 2007; 57: 455-461. https://doi.org/10.1055/s-0031-1296631

Zhang M, Gao F, Cui X, Zhang Y, Sun Y, Gu J, Sun Y, Development and validation of an improved method for the quantitation of sertraline in human plasma using LC-MS-MS and its application to bioequivalence studies. Journal of chromatographic science. 2011; 49: 89-93. https://doi.org/10.1093/chrsci/49.2.89

Jain DS, Sanyal M, Subbaiah G, Pande U, Shrivastav P, Rapid and sensitive method for the determination of sertraline in human plasma using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Journal of Chromatography B. 2005; 829: 69-74. https://doi.org/10.1016/j.jchromb.2005.09.035

Yue X-H, Wang Z, Tian D-D, Zhang J-W, Zhu K, Ye Q, Determination of Sertraline in Human Plasma by UPLC–MS/MS and its Application to a Pharmacokinetic Study. Journal of chromatographic science. 2016; 54: 195-199. https://doi.org/10.1093/chromsci/bmv128

El-Bagary R, Hashem H, Fouad M, Tarek S, UPLC–MS-MS method for the determination of Vilazodone in human plasma: application to a pharmacokinetic study. Journal of chromatographic science. 2016; 54: 1365-1372. https://doi.org/10.1093/chromsci/bmw084

Kall MA, Rohde M, Jørgensen M, Quantitative determination of the antidepressant vortioxetine and its major human metabolite in plasma. Bioanalysis. 2015; 7: 2881-2894. https://doi.org/10.4155/bio.15.207

De Castro A, Concheiro M, Quintela O, Cruz A, López-Rivadulla M, LC–MS/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma: Study of correlation between venlafaxine concentrations in both matrices. Journal of Pharmaceutical and Biomedical Analysis. 2008; 48: 183-193. https://doi.org/10.1016/j.jpba.2008.05.024

Domingues DS, Pinto MAL, de Souza ID, Hallak JEC, Crippa JAdS, Queiroz MEC, Determination of drugs in plasma samples by high-performance liquid chromatography–tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients. Journal of Analytical Toxicology. 2016; 40: 28-36 .https://doi.org/10.1093/jat/bkv107

Sutherland F, Badenhorst D, De Jager A, Scanes T, Hundt H, Swart K, Hundt A, Sensitive liquid chromatographic–tandem mass spectrometric method for the determination of fluoxetine and its primary active metabolite norfluoxetine in human plasma. Journal of Chromatography A. 2001; 914: 45-51. https://doi.org/10.1016/S0021-9673(00)01213-9